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Inherited Thrombocytopenia: Update
on Genes and Genetic Variants Which
may be Associated With Bleeding
Ibrahim Almazni, Rachel Stapley and Neil V. Morgan*
Institute of Cardiovascular Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham,
United Kingdom
Inherited thrombocytopenia (IT) is comprised of a group of hereditary disorders
characterized by a reduced platelet count as the main feature, and often with abnormal
platelet function, which can subsequently lead to impaired haemostasis. Inherited
thrombocytopenia results from genetic mutations in genes implicated in megakaryocyte
differentiation and/or platelet formation and clearance. The identification of the underlying
causative gene of IT is challenging given the high degree of heterogeneity, but important
due to the presence of various clinical presentations and prognosis, where some
defects can lead to hematological malignancies. Traditional platelet function tests, clinical
manifestations, and hematological parameters allow for an initial diagnosis. However,
employing Next-Generation Sequencing (NGS), such as Whole Genome and Whole
Exome Sequencing (WES) can be an efficient method for discovering causal genetic
variants in both known and novel genes not previously implicated in IT. To date, 40 genes
and their mutations have been implicated to cause many different forms of inherited
thrombocytopenia. Nevertheless, despite this advancement in the diagnosis of IT, the
molecular mechanism underlying IT in some patients remains unexplained. In this review,
we will discuss the genetics of thrombocytopenia summarizing the recent advancement
in investigation and diagnosis of IT using phenotypic approaches, high-throughput
sequencing, targeted gene panels, and bioinformatics tools.
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INTRODUCTION
Platelets are small anucleate cells produced by megakaryocytes in the bone marrow (BM) where
they circulate in the blood to protect the integrity of blood vessels. They play an important role in
normal haemostasis to prevent excessive bleeding at the site of blood vessel injury (1, 2). Inherited
Thrombocytopenias (ITs) are a heterogeneous group of disorders characterized by low platelet
counts, often manifesting as bleeding diathesis which subsequently result in impaired haemostasis
(3). In 1948, the disease inheritance pattern of one IT was initially discovered in a disorder called
Bernard-Soulier syndrome (BSS) (4). Since then, the advancement in clinical and scientific research
has led to an increased understanding of the molecular defects in patients with ITs. These defects
are variable in severity, ranging from severe bleeding, which can be recognized within a few weeks
after birth, to mild bleeding that may remain undiagnosed until incidental recognition during
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routine blood testing in adulthood (5). They manifest with
different symptoms including epistaxis, easy bruising, petechiae,
prolonged bleeding from cuts, gum bleeding, excessive bleeding
after surgery, hematuria, and menorrhagia in women (6, 7).
As bleeding is considered the main clinical complication for
patients with IT, some patients with common ITs have the
propensity to develop other disorders such as hematological
malignancies and kidney failure (4, 8). Although there are
other causes of thrombocytopenia, such as infections and
immune disorders, IT is primarily caused by mutations in
genes involved in megakaryocyte differentiation, maturation
and platelet release (9). Since the last decade, next generation
sequencing technologies, namely Whole Exome Sequencing
(WES) and Whole Genome Sequencing (WGS) coupled with
conventional Sanger sequencing and in-silico bioinformatic
tools have been used in parallel to uncover novel genes
with a pivotal role in megakaryocyte biology and platelet
biogenesis (10, 11). To date, 40 genes have been reported
to cause different forms of IT, which reflects the immense
difficulty in identifying a single causative gene, particularly
when accompanied by other hematological disorders [Table 1;
Figure 1; (27, 28, 54)]. These genetic forms have various
clinical manifestations, phenotypic presentations and sometimes
associated with secondary qualitative defects in platelet function
(7). Diverse platelet phenotypes mean there are several
approaches in which they can be characterized. One such way
is to classify genes based on their influence on megakaryocyte
differentiation, platelet production, and removal (54), and will
be discussed below. However, despite these advancements, nearly
50% of patients with IT of unknown genetic etiology still remain
undiagnosed (6, 10).
IT GENES ASSOCIATED WITH
MEGAKARYOCYTE DIFFERENTIATION
AND MATURATION
The process of megakaryopoiesis and thrombopoiesis involves
a complicated biological series of events. Megakaryocytes, like
all blood cells, are derived from the hematopoietic stem cells
(HSC) in the bone marrow during the lineage commitment
stages. The hematopoietic stem cell differentiation process
involves committed precursors that include the commonmyeloid
progenitor (CMP) and the megakaryocyte-erythroid progenitor
(MEP). The erythrocyte cells andmegakaryocyte cells result from
the MEP. Megakaryocyte precursors encompass a maturation
process that results in mature polyploid megakaryocytes, and
then leads to the formation of pro-platelets (54, 55). The process
of megakaryopoiesis and thrombopoiesis involves multiple genes
and transcriptions factors (detailed below) which play important
roles in megakaryocyte differentiation, platelet formation, and
release. IT can result from defects in these genes which present
with variable phenotypic display and clinical presentation.
As a result of the numerous clinical demonstrations of ITs,
they can be characterized based on genes and their role
during megakaryocyte differentiation, platelet production, and
release (9, 56).
Some ITs result from defective changes from haemopoietic
progenitor cells to MKs, leading to reduction or absence in
the number of bone marrow MKs. Thrombopoietin (TPO), an
acidic glycoprotein, is the main regulator of the megakarypoiesis
and thrombopoiesis mechanism in humans, acting through its
receptor c-Mpl. It is required for megakaryocytes to fulfill their
developmental proliferation and for the subsequent maturation
of platelets (57). Affected individuals from a large Micronesian
family displayed idiopathic anemia and mild thrombocytopenia
as a result of mutations in TPO andMPL genes (21, 58). Themain
defective mechanism in several forms of IT is a change in MK
maturation which therefore leads to the production of immature
and dysfunctional MKs. However, the differentiation and
maturation of MKs is regulated by several transcription factors
such as GATA1. GATA1 is highly expressed in the erythroid and
megakaryocytic lineage, and plays a vital role in the maturation
and development of erythroid cells and megakaryocytes (59).
X-linked thrombocytopenia with thalassemia and X-linked
thrombocytopenia with dyserythropoietic anemia are both
caused by mutations in GATA1, resulting in impaired MK and
erythroid cell maturation. As a consequence, GATA1-mutated
patients are characterized with large platelets and reduced α-
granule contents. They also display a variable degree of anemia
and abnormal morphology of red blood cells (60). Additional
transcription factors known to be involved in the maturation of
megakaryocytes are RUNX1, ETV6, ANKRD26, FLI-1, and the
transcriptional repressor GFI1B acting by binding to promoter
regions in MK expressed genes. Thus, multiple mechanisms in
MK and platelet maturation are affected as result of alterations in
these genes (61, 62). A previous study identified a point mutation
in the third helix ofHOXA11 homeodomain causing an inherited
syndrome of congenital amegakaryocytic thrombocytopenia and
radio-ulnar synostosis (19). Thrombocytopenia absent radii
(TAR) syndrome results from a combination of a microdeletion
on Chromosome 1 including the RBM8A gene alongside a
low frequency non-coding single nucleotide polymorphism
(SNP) within the regulatory region of RBM8A (23). As a
consequence, hematopoietic progenitors from patients with TAR
syndrome fail to differentiate into MKs in vitro (63). Gray
Platelet syndrome is characterized by a deficiency in α granule
content which also results in a platelet function defect. It is
associated with enlarged platelets and mild thrombocytopenia
with moderate to severe bleeding as a result of biallelic
mutations in NBEAL2, the gene encoding the neurobeachin-
like-2 protein (22). Variants in the 5’UTR of ANKRD26 cause
familial thrombocytopenia type-2 (THC2) with propensity to
leukemia, which result in loss of RUNX1 and FLI1 binding and
prevents gene silencing (12). Moreover, heterozygous variants
specifically located in the promoter region between c.-134G and
c.-113 region highly affect gene expression. Patients with THC2
are characterized by small MKs with hypolobulated nuclei as
a result of dysmegakaryopoiesis (64). A mutation in the FYB1
gene has recently been identified to cause IT and although
the exact mechanism of the mutation is still ambiguous, it has
been suggested that thrombocytopenia arises from a reduction
of mature MKs in the bone marrow and synthesis of small
platelets (16).
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TABLE 1 | The direct genetic causes of inherited thrombocytopenia and their associated syndromes.
Area of
mutational effect
Gene Syndrome Other syndromic and features References
Megakaryopoiesis ANKRD26 ANKRD26-related thrombocytopenia Predisposition to leukemia. Reduction of platelet α-granules. Normal in
vitro platelet aggregation and mean platelet volume. Some patients
have high level of hemoglobin and leukocyte.
(12, 13)
ETV6 ETV6-related thrombocytopenia Leukemia predisposition. High erythrocyte mean corpuscular volume
(MCV). Some patients have elevated red cell MCV.
(14)
FLI1 Paris-Trousseau
thrombocytopenia/Jacobsen syndrome
Abnormal development of heart and face. Intellectual disabilities. Large
α-granules. Abnormal MKs morphology. Normal RBCs and WBCs
counts. Moderate thrombocytopenia.
(15)
FYB FYB-related thrombocytopenia Small platelets. Reduction of mature MKs in BM. Significant bleeding
tendency. Normal WBCs count. Low mean platelet volume MPV. Mild
iron deficiency anemia.
(16)
GATA1 GATA1-related disease: X-linked
thrombocytopenia (XLT) and X-linked
thrombocytopenia with thalassemia
(XLTT)
Dyserythropoietic anemia. Macrothrombocytopenia. Beta-thalassemia
Congenital erythropoietic porphyria. Erythrocyte
abnormalities. Splenomegaly.
(17)
GFI1B Macrothrombocytopenia and platelet
function defects
Macrothrombocytopenia. Red cell anisopoikilocytosis
Platelet dysfunction. Reduction of platelet α-granules.
(18)
HOXA11 Amegakaryocytic thrombocytopenia with
radio-ulnar synostosis
Bilateral radioulnar synostosis. Severe bone marrow failure. Cardiac
and renal malformations. B-cell deficiency. Hearing loss. Clinodactyly.
Some patients show skeletal anomalies. Some patients have
developed pancytopenia.
(19)
MECOM Congenital amegakaryocytic
thrombocytopenia and radioulnar
synostosis
(20)
MPL Congenital amegakaryocytic
thrombocytopenia (CAMT)
Absence or reduced of MKs in BM. No physical anomalies.
Development to BM aplasia in infancy.
(21)
NBEAL2 Gray platelet syndrome Impaired platelet function. Severe reduction of platelet α-granules
contents. Large platelets. Development of myelofibrosis and
splenomegaly in some patients. Abnormalities in megakaryocyte
development.
(22)
RBM8A Thrombocytopenia-absent radius
syndrome
Bilateral radial aplasia. Elevated hemoglobin level in patients with
5
′
UTR SNP. Normal WBCs count and some patients have leucocytosis
and eosinophilia. Anemia. Skeletal, urogenital, kidney, and heart
defects. Reduced MKs in BM.
(23)
RUNX1 Familial platelet disorder with propensity
to acute myelogenous leukemia
(FPD/AML)
Platelet defects. Variable platelet counts. Reduction in dense granule
secretion observed in secondary qualitative abnormality.
Myelodysplasia. Reduced response to several platelet agonists.
(8)
SLFN14 SLFN14-related thrombocytopenia Giant platelets. Decreased ATP secretion. Reduced number of dense
granules.
(24)
SRC SRC-related thrombocytopenia Myelofibrosis, bleeding, and bone pathologies. Hypercellular bone
marrow with trilineage dysplasia. Platelets are dysmorphic and variable
in size. Paucity of α-granules. Splenomegaly, congenital facial
dysmorphism. Abundant vacuoles.
(25)
THPO Inherited thrombocytopenia from
monoallelic THPO mutation
Bone marrow aplasia. Normal or enlarged platelet morphology. (26)
PTPRJ Inherited thrombocytopenia Syndromic thrombocytopenia characterized by spontaneous bleeding,
small-sized platelets. Impaired platelet function.
(27)
GALE Inherited thrombocytopenia Dysplastic megakaryocytes. Some patients have mild anemia and
febrile neutropenia. Big and pale platelets.
Galactosemia, hypotonia, seizures, jaundice, galactosuria,
and hepatomegaly.
(28)
Platelet
production/
clearance
ACTIN1 ACTN1-related thrombocytopenia Congenital macrothrombocytopaenia. Anisocytosis. Absent or mild
bleeding diathesis.
(29)
CYCS CYCS-related thrombocytopenia Normal platelet size and volume. (30)
GNE GNE myopathy with congenital
thrombocytopenia
Rimmed vacuoles. Hematological complications are rare. Proteinuria
and hematuria in some patients. Membranoproliferative
glomerulonephritis. Platelets size are normal to large.
(31–33)
(Continued)
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TABLE 1 | Continued
Area of
mutational effect
Gene Syndrome Other syndromic and features References
GP1BA Bernard-Soulier Syndrome (BSS) +
platelet type von-Willebrand disease
(PTvWD)
Macrothrombocytopaenia. Severe bleeding tendency with platelet
function defect. Platelet anisocytosis.
(34–36)
GPIBB
GP9
ITGA2B Glanzmann thrombasthenia Impaired platelet function. (37, 38)
ITGB3
MYH9 MYH9-related disease (MYH9-RD) Congenital macrothrombocytopaenia. Mild bleeding tendency.
Development of kidney dysfunction, deafness, cataracts, and
Döhle-like bodies. Elevated liver enzymes.
(39)
PRKACG PRKACG-related thrombocytopenia Giant platelet. Impaired platelet function. (40)
TRPM7 TRPM7-related thrombocytopenia Macrothrombocytopaenia. Atrial fibrillation. (41)
TPM4 Tropomyosin 4-related thrombocytopenia Macrothrombocytopaenia. All other blood cell counts are normal. Mild
effect on platelet function.
(42)
TUBB1 TUBB1-related thrombocytopenia Congenital macrothrombocytopaenia. (43)
WAS Wiskott-Aldrich syndrome, X-linked
thrombocytopenia (XLT)
Mild or severe immunodeficiency, hematopoietic malignancies, and
eczema. Thrombocytopenia with small platelets. Autoimmune
haemolytic anemia.
(44)
FLNA Filaminopathies A X-linked dominant form of periventricular nodular heterotopia
(FLNA-PVNH) and the otopalatodigital syndrome spectrum of
disorders. Hemorrhage and coagulopathy. Abnormal platelet
morphology.
(45)
DIAPH1 Macrothrombocytopenia (MTP) and
hearing loss
_ (46)
Other/unknown ABCG5
ABCG8
Macrothrombocytopenia associated with
sitosterolemia
Xanthomas and pre-mature coronary atherosclerosis due to
hypercholesterolemia. Hematologic abnormalities.
(47)
ADAMTS13 Thrombotic thrombocytopenic purpura Upshaw_Schulman syndrome. Anemia. (48)
STIM1 Stormorken syndrome and york platelet
syndrome
Tubular myopathy and congenital miosis. Severe immune dysfunction. (49, 50)
vWF Von Willebrand disease type IIB (51)
ORAI1 Stormorken syndrome CRAC channelopathy. Severe combined immunodeficiency,
autoimmunity, muscular hypotonia, and ectodermal dysplasia.
(52)
MASTL Autosomal dominant thrombocytopenia _ (53)
DEFECTS IN PROPLATELET FORMATION
AND PLATELET RELEASE
After megakaryopoesis, proplatelets form extensions which lead
to “budding” at the tips and platelet release into the circulation.
Mature MKs undergo essential processing by extending long
branches called proplatelets via the bone marrow sinusoids, and
subsequently release platelets into the blood circulation. These
processes are underpinned by cytoskeletal changes and cellular
signaling where most causative mutations of IT disrupt the
pathway reducing the circulating platelet count (65, 66). Mature
polyploid MKs cytoplasm extend long beaded cytoplasmic
protrusions, as a result of microtubule sliding. The dimerisation
of β1-tubulin with α-tubulin polymerizes into long microtubule
bundles inside the MK cortex. A mixed polarity of microtubule
bundles runs throughout the extension of proplatelets which
are thought to provide fundamental force for microtubule
sliding and proplatelet elongation (65). TUBB1 encodes for
β1-tubulin and mutations within TUBB1 are associated with
an autosomal dominant form of IT known as a congenital
macrothrombocytopenia (43). WASp is a multidomain protein
belonging to a family of actin nucleation-promoting factors
(NPFs) which are specifically expressed in hematopoietic cells.
WASp plays an important role in actin polymerization by
transmission of surface signals via the actin-related protein
(Arp)2/3 complex (44, 67). Mutations have been identified in the
WAS gene which cause a rare X-linked disorder called Wiskott-
Aldrich syndrome (WAS). Patients are characterized by micro-
thrombocytopenia and immunodeficiency with predispostion to
malignancies (68). The transmission of extracellular signals into
the cytoskeleton is mediated via membrane bound receptors
which have been associated with mutations in IT. One of the
main membrane receptors in platelets/MKs is the GP1b-IX-
V complex, which binds specifically to Von-Willebrand factor
(VWF). This receptor is comprised of four subunits including
GP1bα, GP1bβ, GPIX, and GPV. Binding of VWF with GP1bα
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leads to activation and signal transmission to form the extending
proplatelet. Mutations in the encoding genes GP1BA, GP1BB,
and GP9 cause monoallelic and biallelic forms of BSS (69, 70).
Other receptors include the receptor for fibrinogen, integrin
GPIIb-IIIa, which is encoded by the genes ITGA2B and ITGB3.
Affectedmutations in ITGA2B and ITGB3 have been identified to
cause Glanzmann thrombasthenia (GT) (71), but patients have a
normal platelet count.
INITIAL DIAGNOSIS OF
HEREDITARY THROMBOCYTOPENIA
Identification of the genetic cause in patients with IT is
challenging and many patients may be misdiagnosed with
acquired thrombocytopenia such as immune thrombocytopenic
purpura (ITP). IT can be recognized in patients when a low
platelet count has been identified after birth, the presence
of familial medical history with similar clinical presentations,
evaluation of peripheral blood films, and physical examination.
Moreover, the presence of a severe bleeding tendency (in
combination with a low platelet count), a lifelong history of
diathesis, and evidence of other clinical complications that are
typically associated with thrombocytopenia in syndromic forms,
and all help to diagnose IT (4, 72). Platelets are involved in
other biological roles beyond hemostasis, such as immunity and
inflammation (73–75) therefore, mutations in platelet specific
genes may cause functional disruption in hemostasis, other
biological pathways or both. Furthermore, some proteins are
expressed in megakaryocytes and platelets and can be found
in other cell types. GATA1 is a prominent example which
involves megakaryopoiesis and erythropoiesis (76). MYH9 also
has an important role in the platelet cytoskeleton and has
been found expressed in kidney and inner ear cilia (77).
Based on this, inherited bleeding disorders can be classified
into three categories including disorders that (i) affect only
platelets, (ii) disorders that are associated with syndromic or non-
syndromic phenotypes, and (iii) disorders with increased risk of
haematologic malignancies. This classification can be used for
both diagnostic and prognostic purposes (4, 11).
SYNDROMIC DISORDERS ASSOCIATED
WITH IT
The number of IT forms identified has increased over the
last few years since the implementation of NGS. Consequently,
it has been shown that the bleeding is not the only clinical
phenotype with IT, but patients with some IT forms have
propensity to develop more syndromic disorders as result of
molecular defects in genes responsible for thrombocytopenia.
For instance, hematological malignancies, bone marrow aplasia,
skeletal malformation, liver and kidney malfunction, and
deafness (Figure 2). The development of these diseases can be
more severe for patients than the bleeding itself (4) however, it
is still important to recognize if these manifestations are present
in the relatives. Some syndromic phenotypes associated with
ITs are variable between family members or can arise later in
life. For example, development of deafness, kidney malfunction
and/or cataract in patients with MYH9-RD occur only in adult
individuals and it has been reported that patients of the same
MYH9-RD pedigrees have variable clinical manifestations (78).
THE GENETIC DIAGNOSIS OF IT
Some patients with a low platelet count may be falsely diagnosed
and receive unnecessary treatments such as immunosuppression
and splenectomies and therefore it is paramount that strong
evidence must prove that the condition is truly genetic. Genetic
diagnosis is a vital approach in providing patients with clinical
benefits and prevent unnecessary treatments. Patients with
genetic mutations in RUNX1 have a predisposition to develop
hematological malignancies where the genetic information can
be used to monitor the patients’ hematological parameters
very closely. This emphasizes the importance and need for
definitive genetic diagnostic tools to provide quick and cost-
effective diagnosis for screening patients with IT (6, 8). The
molecular basis of ITs has been elucidated since the adoption of
Sanger sequencing and linkage analysis in the 1990s. Recently,
Sanger sequencing is considered a low throughput and time-
consuming approach which can be used initially as a standard
tool to investigate patients based on precise clinical findings
and phenotype (4). A targeted thrombocytopenia gene specific
panel is a useful approach which can be used as initial screening
prior to WES. This targeted panel encompasses all known genes
associated with IT and their related genes. The aim of using
an IT gene specific panel is to filter out patients based on
variants in known IT-causal genes and subsequently allowing
for WES for patients with unknown genetic etiology (4, 6).
The ThromboGenomics project provided a multi-gene high-
throughput sequencing platform (HTS) for the diagnosis of
heritable bleeding disorders (79). The HTS platform covers
approximately 96 genes associated with inherited bleeding,
thrombotic, coagulation, and platelet disorders. The panel
showed high sensitivity in detecting causative variants in patients
who had not been previously investigated at the molecular level.
It has a high sensitivity to detect variants in the exonic region
as well as many of exonic-intronic boundaries and untranslated
regions (UTRs) (6, 79).
NEXT GENERATION SEQUENCING
Targeted NGS platforms can be efficiently applied to determine
the causative genes of IT. As the molecular basis of ITs
remain unknown in many patients, WGS or WES may
be required which improves the knowledge of ITs at the
molecular level. Several national and international consortia
have adopted these approaches to identify disease-causing genes
associated with IT. The genes SLFN14, FYB, STIM1, GFI1b,
and ETV6 are some examples of causative genes detected by
these approaches. The results obtained by HTS improves the
understanding of the functional role in some causative genes,
whose function in platelet production was previously unknown.
These techniques will bring substantial benefits to improve our
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FIGURE 1 | IT causative genes involved in megakaryopoiesis, platelet formation, and others. The differentiation of platelets from HSCs proceeds by multiple different
cell lineages which involve many genes encoding a number of transcription factors and proteins. Genetic defects in these genes have been shown to cause IT. HSC,
Hematopoietic stem cell; MPP, Multi-Potent Progenitor; CMP, Common myeloid progenitor; MEP, Megakaryocyte-erythroid progenitor.
FIGURE 2 | Schematic representation of the defects associated with syndromic IT. JBS, Jacobsen syndrome; RD, related disease; TAR, Thrombocytopenia-absent
radius; GPS, Gray platelet syndrome; SS, Stormorken syndrome; WAS, Wiskott-Aldrich syndrome; YPS, York platelet syndrome.
understanding of the molecular mechanisms in megakaryocyte
and platelet biogenesis (14, 16, 24, 49, 80, 81). However,
distinguishing pathogenic variants from non-pathogenic variants
often requires complex functional and cell line studies to prove
causality (7).
BIOINFORMATIC TOOLS
Bioinformatic tools can be conducted to determine candidate
variants from WES or WGS data. A wide range of variants,
∼25,000–40,000 variants can be identified per single patient
in WES. These variants can be filtered for novelty by direct
comparison using a database from the 100,000 Genomes
Project, Exon Variant Server (EVS), dbSNP versions, Exome
Aggregation Consortium (ExAC) (gnomAD), and in-house
databases of whole exomes and/or whole genomes. A database
of known platelet-related genes and genes involved in platelet
formation, function, lifespan, or death can be compared with
the patient’s genes in order to narrow the candidate genetic
variants down. Variants with MAF (minor allele frequency)
≥0.01 are generally excluded given the rarity of most of
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these genetic defects in IT. Variants not known to change
the amino acid or those that do not have a potential effect
on protein, such as synonymous variants and intron variants
can also be excluded. Splice site variants occurring >5 base
pair away from the exome can be also excluded, although
this can potentially result in splicing or regulatory mutations
being missed. Comparisons with other affected and unaffected
family members on the database can be used to select candidate
variants. Also, pathogenicity prediction can be assessed by using
different tools such PolyPhen2, Provean, SIFT, Mutation Taster,
mRNA expression levels which predict the potential effect of
amino acid changes on protein structure and function and also
measure the conservation of amino acids among different species.
Sapientia is a recently developed clinical diagnostic platform
established by Congenica to help clinicians, clinical scientists,
and researchers with genetic diagnosis and identification of
disease-causing genes, by interrogating the human genome
with multiple bioinformatic tools. It can help streamline the
process of diagnosis, ensuring patients are receiving accurate
information and treatments for their individual platelet or
megakaryocyte defect.
CONCLUSIONS
The advances in NGS techniques improves our knowledge about
the molecular mechanisms of IT. The major risk factor for
patients with ITs is the development of additional syndromic
disorders rather than bleeding itself. Due to the polygenic nature
of ITs and disorders involved in hematopoiesis, identifying a
singular causative gene for platelet andmegakaryocyte function is
particularly difficult. A combination of whole blood counting and
platelet functional assays will highlight the platelet phenotype,
however only familial studies and genetic sequencing will help
to identify any genetic defect. With the introduction of HTS
and various genome browser software such as Sapienta, the
diagnosis process has been modernized to highlight candidate
variants in known platelet affected genes and reveal variants in
novel genes in which hemostatic input remains to be explored.
Approaches such as these may be implemented within clinical
settings in the future, however, bioinformatic pipelines are yet
to be standardized across all facilities. Aside from bioinformatic
training and the initial financial burden of installation of the
software, there are clear reasons that updating current genetic
analysis in hematological disorders benefits healthcare in the
wider community. This will ensure IT families obtain a clear
diagnosis and receive correct treatment based on their genetically
influenced megakaryocyte or platelet defect.
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